D
ementia cases have been increasing as the population ages in developed countries, leading to a major burden on healthcare systems. These expenses have now surpassed that of cancer and cardiovascular disease in the United States 1 In 2015, the World Health Organization announced that the total number of people with dementia will reach 75.6 million in 2030, and almost triple that number by 2050 to 135.5 million, in contrast with improvements in the management of other chronic diseases. 2 Pure vascular dementia (VaD) is caused by impaired cerebral blood flow with damaged blood vessels, potentially because of stroke. Although Alzheimer disease is the most common form of dementia, followed by VaD, recent clinical studies have revealed that mixed dementia (a combination of VaD and Alzheimer disease) is likely the most common cause of cognition disorders, suggesting that vascular factors play a pivotal role in cognitive pathology. Against that background, a novel concept, vascular cognitive impairment (VCI), has been proposed, which invites therapeutic strategies that focus on the blood vessels. 3 This idea encompasses the entire spectrum of cognitive disorders associated with all forms of cerebral vascular brain injury, not solely stroke, ranging from mild cognitive impairment through fully developed dementia. 3 Cerebrovascular damage is one of the main pathological processes leading to blood-brain barrier (BBB) disruption. Cerebral microangiopathies, one major cause of VaD, are characterized by vascular wall thickening, collagen deposition, degeneration of smooth muscle cells, and narrowing of the lumen and are often associated with BBB breakdown. 4 Indeed, many studies have shown a significant association between BBB dysfunction and dementia progression, including Alzheimer disease. 5, 6 Therefore, an understanding of the molecular mechanisms that regulate BBB permeability and disruption is essential for establishing future therapeutic strategies to alter dementia disease progression associated with cerebrovascular injury. However, despite the high level of need, there are currently no highly effective strategies for the treatment or prevention of VCI.
MicroRNAs (miRs) are small, single-stranded RNAs, usually ≈22 nucleotides in length, that repress the expression of mRNAs by binding to 3′-untranslated regions (3′UTR) that are entirely or partially complimentary. The number of different mRNAs that may be affected by a single miR is estimated to be in the hundreds. On the basis of the high frequency of base pair matches found, highly validated computational programs predict that almost 60% of human protein-coding genes may be post-transcriptionally modulated by miRs. 7 Thus, a single miR may influence many major (patho)physiological processes. The study of miRs and their regulatory effects currently represents one of the most active areas of research in genomics. Not surprisingly, miRs seem to be key regulators of numerous complex genetic programs relevant to cardiovascular pathology, including cardiac development, endothelial function, lipid metabolism, ventricular hypertrophy, arrhythmias, and vascular disease. 8 Recent evidence has also revealed the important role of miR regulation in various neurological diseases, such as Alzheimer disease, traumatic brain injury, and stroke. [9] [10] [11] However, the role of miRs in VCI progression remains unclear.
Bilateral common carotid artery occlusion in rats has been widely used as a VaD model of chronic cerebral hypoperfusion. 12 However, accurate behavioral assessment of this rat model is often hampered by loss of the visual pathway caused by occlusion of the ophthalmic arteries. Therefore, in the present study, we used a novel mouse model of cognitive impairment, produced by bilateral common carotid artery stenosis (BCAS) with microcoils. [13] [14] [15] [16] Because BCAS surgery in mice induces a milder decrease in the cerebral blood flow than bilateral common carotid artery occlusion, this model develops less pronounced damage to the visual pathway and maintains residual blood flow within the common carotid arteries and branches, including the ophthalmic arteries. 15 Pathology of the BCAS mouse model is commonly characterized by memory deficits with white matter lesions and BBB breakdown, making it ideal for the present study. 13, 15, 16 In this study, we investigated the role of miRs in the progress of dementia caused by cerebral hypoperfusion and identified a specific miR, miR-501-3p, as a potential therapeutic tool for VCI.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Cell Cultures
Mouse bEnd3 cells and HEK293 (human embryonic kidney 293; ATCC) cells were cultured in DMEM (GIBCO; number 11885-084) containing 10% fetal bovine serum (Atlanta Biologicals; catalog number: S11150) at 37°C in a 5% CO 2 and 95% air humidified atmosphere. Human cerebral microvascular endothelial cells (hCMEC/ D3; Millipore; catalog number: SCC066) were cultured in collagen type I-coated dishes and grown in EGM-2 Complete Media (Lonza; catalog number: CC-3162). All experiments were performed between passages 3 and 6.
Tumor Necrosis Factor-α, Hydrogen Peroxide, and Interleukin-6 Stimulation Study
The culture medium was replaced with fresh medium containing recombinant mouse TNFα (tumor necrosis factor-α; 1, 10, and 100 ng/mL; Sigma-Aldrich; catalog number: T7539) for 24 hours, hydrogen peroxide (250 and 500 µmol/L) for 12 hours, or IL-6 (interleukin-6; 1, 10, and 100 ng/mL; Sigma-Aldrich; catalog number: 19646) for 12 hours.
Transfection of Cultured Cells
Transfections of bEnd3 and HEK293 cells were performed using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen; catalog number: 13778) mixed with anti-mmu-miR-501-3p (inhibitor; Ambion; catalog number: MH11510), anti-hsa-miR-501-3p (inhibitor; Ambion; catalog number: MH12927), pre-mmu-miR-501-3p (mimic; Ambion; catalog number: MC11510), pre-hsa-miR-501-3p (mimic; Ambion; catalog number: MC12927), or scrambled controls (Ambion) with final concentrations of 50 nmol/L in serum-free medium (Opti-MEM; GIBCO; catalog number: 31985-070). Cells were treated with TNFα for 24 hours after transfection and were harvested by QIAzol Reagent (QIAGEN; catalog number: 79306).
Luciferase Reporter Assay
As previously reported, 17 direct targeting of the ZO-1-3′UTR by miR-501-3p was confirmed by transfecting HEK293 and hCMEC/ D3 cells with luciferase constructs. Cells were transfected with plasmids containing either empty vector or ZO-1-3′UTR, using Lipofectamine 3000 (Invitrogen; catalog number: L3000-008). The cells were then transfected a second time after 36 hours with either miR-501-mimic or scr-miR (Applied Biosystems) and incubated for 24 hours. Luciferase activity was determined by Lightswitch Assay (Switchgear; catalog number: LS010) as per protocol.
Immunohistochemistry
To determine the change in ZO-1 expression in mouse endothelial cells, post-transfection of pre-/anti-miR-501-3p, anti-ZO-1 antibody (Invitrogen; catalog number: 61-7300, rabbit, working concentration: 1.25 µg/mL) was visualized with Alexa Fluor 488 antirabbit IgG secondary antibody (Invitrogen; catalog number: A11008, goat, working concentration: 2 µg/mL) and counterstained with 4′, control tissue was incubated with no primary antibody, followed by incubation with secondary antibody and detection reagents.
Transendothelial Electric Resistance Test
As per previous reports 18, 19 but with minor modifications, bEnd3 cells were seeded on Collagen Type I (BD Biosciences) coating well inserts membrane (Millicell Cell Culture Insert, diameter 12 mm, hydrophilic polytetrafluoroethylene, pore size, 0.4 µm; Millipore).
The resistance values in cell layers were measured using a voltage/ ohm meter (Millicell ERS-2; Millipore). Resistance values of each well were calculated after subtracting that of the blank well (no cell seeding) and then multiplying the resulting values by membrane area. Medium was replaced by fresh medium before measurement.
Isolation of Mouse Cerebral Endothelial Cells
We evaluated the miR-501-3p expression levels in cerebral endothelial cells in vivo, by isolating the midportion of the white matter from 9-week-old male C57/BL6J mouse brains post-BCAS surgery after 48 hours under microscopy and dividing them into small pieces. Using previously published methods 13 with minor modifications, the tissues were dissociated by up-and down-strokes with a 10 mL pipette in DMEM (GIBCO) containing 0.1% collagenase/dispase (Roche Diagnostic GmbH; catalog number: 10269638001) and 20 μg/mL DNase I (Sigma-Aldrich; catalog number: D5025) and were incubated at 37°C with occasional agitation. After centrifugation, the pellet was resuspended to remove myelin in 20% bovine serum albumin in DMEM and centrifuged at 1000g for 10 minutes. Cerebral endothelial cells were separated using the EasySep Mouse PE selection kit (STEMCELL Technologies, Inc; catalog number: 18554) via PE-labeled antimouse CD31 antibody (Bio Legend; catalog number: 102407) for the selection of endothelial cells. Purity of cerebral endothelial cell selection was evaluated by flow cytometry. Further, markers of pericytes (monoclonal allophycocyanin-conjugated anti-CD140b [PDGFRB (platelet-derived growth factor receptor β)]; eBioscience; catalog number: 17-1402-80; working concentration: 5 µg/mL), astrocytes (monoclonal allophycocyanin-conjugated anti-GFAP [glial fibrillary acidic protein]; Miltenyi Biotec; catalog number: 130-105-328; working concentration: 10 µg/mL), and CD45-positive immune cells (allophycocyanin-conjugated antimouse CD45; BioLegend; catalog number: 103111; working concentration: 2.5 µg/mL) were used to determine whether the isolated endothelial population contained other cell types. Both cerebral endothelial fraction and endothelial-excluded fraction were stocked for later analysis.
Primary mouse cerebral endothelial cells were isolated from 4-to 6-week-old C57/BL6 mouse brains after removing the cerebellum, and the above-described endothelial isolation methods are found in the first paragraph of the same methods section. The endothelial cell fraction was cultured in collagen type I-coated dishes and grown in EGM-2 Complete Medium containing 10% fetal bovine serum (Atlanta Biologicals; catalog number: S11150) at 37°C in a 5% CO 2 and 95% air humidified atmosphere. The cells were used only at passage 2.
Animals
C57BL/6 wild-type male mice were purchased from the Jackson Laboratory. Animals were housed in a temperature-controlled and humidity-controlled room under a 12-hour light/dark cycle (6:30/18:30). All animal protocols were approved by the VA Institutional Animal Care and Use Committee and followed the National Institutes of Health and U.S. Department of Agriculture Guidelines for Care and Use of Animals in Research.
Procedure of BCAS Surgery
As previously described, 13 9-week-old C57BL/6J male mice weighing 24 to 26 g were anesthetized with inhaled 2% isoflurane. Mice were held on a warming pad with body temperature controlled to 37°C during the surgical procedure. The neck hair was gently removed with a hair removal cream and scrubbed with alcohol and iodine before opening the neck. Chronic cerebral hypoperfusion was induced by applying microcoils (inner diameter: 0.16 mm) to both common carotid arteries. Through a midline cervical incision, both common carotid arteries were exposed and freed from their sheaths. The arteries were gently lifted by the suture, and the loops of the microcoil were placed below the carotid bifurcation. The microcoil was twined by rotating it around the common carotid artery. Mice in the control group underwent sham operation. Sham-operated animals underwent bilateral exposure of the common carotid arteries without applying the microcoil. The wounds were closed with nylon/polypropylene monofilament suture, and the mice were recovered in their cages with free access to food and water. The procedure took ≈20 minutes. To help alleviate pain, all animals received bupivacaine 0.1 mg/kg (1-3 drops on the cut) and buprenorphine (0.05 mg/kg) every 12 hours for up to 3 days post-surgery.
Cerebral Blood Flow Measurement
As previously described, 13, 15, 20 cerebral blood flow was quantified in all operated mice using a Laser Speckle Blood Flow Imager (OMEGAZONE (Mini); Omegawave) under deep anesthesia with 2% isoflurane. Mice were held on a warming pad with body temperature controlled to 37°C during the procedure. The scattered light was filtered through a hybrid filter to detect only scattered light that had perpendicular polarization to the incident laser light, enabling stable and specific measurements. Color-coded blood flow images, obtained in high-resolution mode (638×480 pixels; 1 image/s), were captured by a CCD camera positioned overhead. Images were analyzed using the incorporated color image program to obtain the average blood flow value. This was expressed as a percentage of the preoperation baseline blood flow.
Administration of LNA-Modified Antisense miR-501-3p
In the Exiqon Guidelines, intravenous injection is not recommended because it results in high peak plasma concentrations of locked nucleic acid (LNA)-modified antisense oligonucleotide immediately after administration, which can occasionally cause sequence-dependent acute toxicity. Further, the procedure can cause the tail vain to collapse after a few injections. Accordingly, we selected intraperitoneal injection in the present study. Either LNA-anti-miR-501-3p (custom made by Exiqon) or scrambled miR as control (negative control B; product number 199900; batch number 681121; Exiqon) were intraperitoneally injected. The concentrations of anti-miR or scrambled miR included both 1 and 10 mg/kg-body weight. A single injection was performed 1 hour after BCAS surgery.
Experimental Timeline of Behavior Tests
We used 2 independent cohorts to assess behavior. 
Y-Maze Test
According to previous methods 13 with minor modifications, spatial working memory was evaluated by assessing spontaneous alterations of behavior in the Y-maze test. Mice were placed at the end of an arm and allowed to move freely through the maze for 8 minutes during the dark period (18:30 to 6:30) . A video camera was positioned over the experimental box, and mouse behavior was video tracked for analysis (TopScanLite; Clever Sys, Inc). Spontaneous alterations were defined as the consecutive entry of a mouse into all 3 different arms to form a triplet of nonrepeated components. The percentage of spontaneous alterations was calculated as the ratio of actual-to-possible alterations (defined as the number of spontaneous alterations in behavior/[the total number of arm entries−2]×100).
NOR Test
The NOR test was performed in a 45×45×45 cm plastic box. Before the training session, the mouse explored the experimental plastic box freely without objects for 5 minutes to habituate it (adaptation session). Then, mice were allowed to explore freely for 10 minutes (training session), but 2 identical objects (tower of Lego bricks) were present. Twelve hours later, one of the objects was replaced by a novel object (flask filled with sand). The mouse was placed in the box again and allowed to explore it for 10 minutes (trial session). A video camera was positioned over the experimental box, and mouse behavior was video tracked for analysis (TopScanLite). Exploration was defined as sniffing or touching the stimulus object with the nose. Sitting on or walking aimlessly around the objects was not considered exploratory behavior. Number of instances of contact with each object and the total time spent exploring around each object were automatically recorded.
Open-Field Test
Mice were placed individually and unrestrained in an open-field 45×45×45 cm plastic box for 5 minutes during the dark period (18:30 to 6:30). A video camera was positioned over the experimental chamber, and mouse behavior was video tracked for analysis (TopScanLite). Time spent in the center of the floor area was used to determine relative anxiety. Total distance and number of trips into the center area were also calculated as markers of anxiety-like behaviors.
Light and Dark Transition Test
A 45×45×45 cm plastic box was divided into 2 chambers with a hole between them, one of which was brightly illuminated (100 Lux) and the other dark. For the test, individual mice were placed into the light side and allowed to move freely for 5 minutes during the dark period (18:30 to 6:30). A video camera was positioned over the experimental chamber, and mouse behavior was video tracked for analysis (TopScanLite). The total time spent in the dark side was automatically recorded and used to determine the anxiety response.
Wire Hang Test
To evaluate motor function and deficits, individual mice were placed on the cage top during the light period (6:30 to 18:30), which was then inverted and suspended above the home cage. The time to fall was recorded by stopwatch. Experimental time was 5 minutes per session, and average time of 2 sessions was used for analysis.
Assessment of White Matter Lesions and Hippocampal Neurons
Brain samples were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 4-µm-thick coronal sections. Sections were subjected to Klüver-Barrera staining for the measurement of white matter lesions in the corpus callosum. According to the previously described methods, 13, 15, 21 the severity of white matter lesions was graded as normal (grade 0), disarrangement of the nerve fibers (grade 1), the formation of marked vacuoles (grade 2), and the disappearance of myelinated fibers (grade 3) in the corpus callosum.
To evaluate hippocampal neurons, sections were subjected to Nissl staining. Normal pyramidal cells showed round and pale stained nuclei, whereas dying or dead cells showed pyknotic nuclei. 22 Numbers of normal neurons in the CA1-hippocampal layer were counted to obtain neuronal density using the ImageJ software.
Evans Blue Extravasation
BBB dysfunction post-BCAS surgery was evaluated according to previous methods 13 with minor modification. Forty-eight hours after BCAS induction, mice were injected IP with 1 mL of 1% Evans blue (Sigma-Aldrich; catalog number: E-2129). After one additional hour, anesthetized mice were perfused with saline to wash out excess Evans blue and then euthanized. We performed quantitative measurement of Evans Blue extravasation according to previous methods with minor modification. 23, 24 Coronal sections of brain that included white matter were homogenized in PBS and 100% trichloroacetic acid solution (final concentration 25%) and then cooled overnight at 4°C and centrifuged for 30 minutes at 10 000g. The fluorescence (excitation 620 nm/emission 680 nm) of the supernatant was determined.
Brains were snap-frozen and sectioned into 10-µm-thick slices. Sections were stained with anti-CD31 antibody (rabbit, 1:200 dilution; Abcam; catalog number: ab28364) visualized with Alexa Fluor 488 antirabbit IgG secondary antibody (goat, working concentration: 4 µg/mL; Invitrogen; catalog number: A11008). Extravasated Evans blue from CD31-stained microvasculature in the paramedian portion of the corpus callosum was evaluated under fluorescence microscopy at fluorescent wavelength 680 nm.
For further quantification and according to previous methods, 13 the area of extravasated Evans blue was measured using ImageJ software, as an approximate index of BBB breakdown. Image analysis focused on the paramedian portion of the corpus callosum facing the dorsal part of the lateral ventricle, because white matter lesions were most intense in this region.
Quantitative Real-Time Polymerase Chain Reaction
According to the previously described manufacturer's instructions, 25 TaqMan microRNA Reverse Transcription Kit (Applied Biosystems; catalog number: 4366596) was used for miR reverse transcription. TaqMan Assay Kits (Applied Biosystems) for hsa/mmu-miR-122-5p (catalog number: 002245), hsa/mmu-miR-124-3p (catalog number: 001182), mmu-miR-497-3p (catalog number: 46318), hsa/mmu-miR-144-3p (catalog number: 002676), mmu-miR-511-3p (catalog number: 463069_mat), mmu-miR-302b-5p (catalog number: 001307), mmu-miR-302d-5p (catalog number: 462569_mat), mmu-miR-500-3p (catalog number: 002606), hsa-miR-501-3p (catalog number: 002435), mmu-miR-501-3p (catalog number: 001651), mmu-miR-501-5p (catalog number: 001356), snoRNA202 (endogenous control for normalization in mice; catalog number: 001232) and RNU44 (for human samples; catalog number: 001094) were used. To synthesize first-strand cDNA from mRNA, SuperScript VILO cDNA Synthesis Kit (Invitrogen; catalog number: 11754-250) was used. Specific oligonucleotide primers for target sequences are found in Table III in the online-only Data Supplement. GAPDH was used as an internal control for normalization. For primary mouse cerebral endothelial cells, 18S (Applied Biosystems; catalog number: 4318839) was used as an internal control for normalization. TaqMan quantitative real-time polymerase chain reaction assay for human-specific primers of claudin-5 (Applied Biosystems; catalog number: Hs00533949_s1) was also used. All fold changes were calculated by the method of ∆∆Ct.
Statistical Analysis
Data were expressed as the mean± SEM, and P<0.05 was considered statistically significant. Depending on the normal distribution, 1-way ANOVA and Kruskal-Wallis test with post hoc test were used to compare the different groups. To compare the values between 2 groups, depending on the normal distribution, Student t test or MannWhitney test were performed. Standard Kaplan-Meier analysis was used to compare the survival rate in the groups. All statistical analyses were performed using GraphPad Prism 5 Software.
Results

Effects of TNFα on Tight Junctions of Brain Vascular Endothelial Cells
A neurovascular unit consists of microvessels (consisting of endothelial cells, basal lamina matrix, astrocyte end feet, and pericytes), astrocytes, neurons, and their axons, in addition to other cell types (microglia and oligodendrocytes). BBB breakdown is thought to be an initiating event in neurovascular unit dysfunction. In particular, cerebral endothelial cell dysfunction resulting in loss of tight junctions (TJ) is thought to precede neurovascular unit impairment because of ischemic conditions. As such, cerebral endothelial cell-TJ molecules, in particular, claudin-5 and ZO-1 (tight-junction protein 1), play important roles in BBB permeability and thereby neuronal disease progression. 13, 26, 27 Several factors, such as TNFα, IL-6 (interleukin-6), oxidative stress, and angiotensin II, can lead to BBB disruption via TJ protein expression changes and potentially alter TJ expression through changes in miR transcription levels. 28 Among these, TNFα plays a critical role in the progress of BBB breakdown through cerebral endothelial TJ disruption and ischemia-induced BBB disruption. 13, 29, 30 Indeed, several clinical studies have shown the beneficial effect of TNFα inhibition on dementia, including Alzheimer disease. 31, 32 As shown in Figure 1A , TNFα stimulation of murine brain vascular endothelial (bEnd3) cells significantly decreased cerebral endothelial claudin-5, ZO-1 and ZO-2 (tight-junction protein 2), occluding, and LSR (lipolysis-stimulated lipoprotein receptor; tricellular TJ) gene expression levels. Because claudin-5, ZO-1, and occludin are key TJ proteins in maintaining the BBB, we next attempted to identify regulatory miRs for claudin-5, ZO-1, and occludin.
miR Candidates Predicted to Modulate Claudin-5, ZO-1, and Occludin
In silico analysis (miRWalk version 2.00; The Database on Predicted and Validated microRNA Targets) 33 identified multiple miRs that could target human and mouse claudin-5, ZO-1, and occludin for translational repression or mRNA degradation. To maximize the potential for human translation, we specifically focused on candidate miRs that prediction algorithms suggested had strong conservation of effects for both mouse and human. As we reported previously, 28 miR-122-5p, 124-3p, and 497-3p were candidates for 3′UTR suppression of claudin-5. Further, as shown in Tables I and II in the online-only Data Supplement, miR-144-3p, 501-3p, and 511-3p were candidates for suppression of ZO-1 and miR-302b-5p and 302d-5p for suppression of occludin.
Expression of Mouse Brain Endothelial Cell miRs With TNFα Treatment
We next monitored the expression of the abovementioned candidate miRs with TNFα stimulation in bEnd3 cells. We found that miR-122-5p, miR-124-3p, miR-144-3p, and miR-511-3p were not differentially regulated, whereas miR-497-3p (candidate for claudin-5) and miR-501-3p (candidate for ZO-1) were increased significantly by TNFα stimulation of mouse bEND3 cells ( Figure 1B ). Other stimuli including IL-6 and oxidative stress have been shown to regulate BBB disruption. 28, 34 However, treatment with IL-6 or hydrogen peroxide did not affect TJ gene expression in vitro ( Figure IA and IB in the online-only Data Supplement).
Characteristics of Chronic Cerebral Hypoperfusion-Induced VCI Murine Model
The above-described in silico and in vitro results suggest that elevation of miR-497-3p or miR-501-3p might induce significant reduction of cerebral endothelial TJ function under TNFα stress conditions, with important implications for hypoperfusion-induced BBB dysfunction. To evaluate the role of these miRs on TJ constituents in VCI disease progression, we used a murine VCI model involving BCAS, a procedure in which microcoils are surgically placed around the common carotid artery. 13, 21 We chose to study male mice in the present study, in part because the incidence of VaD is higher in men in comparison to women 35 and also because male mice have been featured in previous studies using this method. 13, 21 As mentioned previously, 13 BCAS surgery significantly reduced cerebral blood flow (Figure 2A ), resulting in white matter lesions at the paramedian portion of the corpus callosum ( Figure 2B ), as well as hippocampal pyknotic neuronal injuries ( Figure IIA in the online-only Data Supplement). The manipulation/stenosis of the carotids used in this model does not alter the blood pressure.
13,21
Effect of Cerebral Hypoperfusion on White Matter and Hippocampal TJs and TNFα Gene Expression
To further investigate the effects of BCAS surgery, we monitored expression levels of TJ-related genes and found a significant reduction in claudin-5 and ZO-1 gene expression levels in white matter tissue 28 days after induction of chronic cerebral hypoperfusion ( Figure 2C ), although levels of these genes were not altered in the hippocampus ( Figure IIB in the online-only Data Supplement). Further, TNFα gene expression within the white matter was increased significantly from 24 hours post-BCAS surgery but not in hippocampus ( Figure 2D ).
Expression of White Matter MiR-501-3p in the Cerebral Hypoperfusion-Induced VCI Murine Model and Its Relation to White Matter TNFα
As described above, we hypothesized that cerebral hypoperfusion induced white matter TNFα, resulting in increased expression of miR-497-3p and miR-501-3p. This would result in inhibition of claudin-5 and ZO-1 levels in white matter lesions as a part of VCI disease pathogenesis. To test this hypothesis, we evaluated miR-497-3p and miR-501-3p expression levels in white matter and found that only miR-501-3p was increased by 48 hours after BCAS surgery ( Figure 2E ), whereas miR-497-3p was not ( Figure 2F) . Again, the hippocampus was spared, with miR-501-3p in BCAS mice remaining unchanged ( Figure IIC in the online-only Data Supplement).
To examine whether miR-501-3p was elevated in cerebral endothelial cells, we isolated endothelial cells from white matter (using CD31 capture-magnetic beads; Figure 2G ), achieving endothelial cell purification of >95% ( Figure 2H and 2I) . Although the CD31 magnetic bead method can pull down other cell subtypes (ie, pericytes, astrocytes, and CD45-positive immune cells 36 ), marker expression for pericytes (CD140b [PDGFRB] ), astrocytes (GFAP), and CD45-positive immune cells showed that these represented only a small fraction of the isolated CD31-positive cells (Figure 2H and 2I) . Although miR-501-3p expression level was higher in the nonendothelial cell population than in cerebral endothelial cells at baseline ( Figure 2J ), we found that miR-501-3p was, indeed, elevated in endothelial cells after BCAS ( Figure 2K) but not in the nonendothelial cell population ( Figure 2L ). We also observed increased miR-501-3p levels in murine white matter after intraperitoneal injection of recombinant TNFα ( Figure 2M ). Finally, using primary mouse brain endothelial cells, we found that TNFα significantly increased miR-501-3p expression and in a similar fashion to bEnd3 cells ( Figure 2N) .
As is well known, 2 mature miRs can originate from opposite arms of the same pre-miRNA, denoted -3p or -5p. Interestingly, in silico analysis using Targetscan 37 also indicated that miR-501-5p might regulate ZO-1 in mice and humans ( Figure IIIA and IIIB in the online-only Data Supplement). Although both miR-501-5p and miR-501-3p were elevated with TNFα treatment of bEnd3 cells ( Figure  IIIC in the online-only Data Supplement), BCAS surgery showed that miR-501-5p decreased over time when adjusted for miR-501-3p levels ( Figure IIID in the online-only Data Supplement). We, therefore, think that miR-501-3p is the dominant transcript in this environment.
Regulatory Role of miR-501-3p in the Expression of Cerebral Endothelial ZO-1
To further determine whether miR-501-3p regulates ZO-1 levels, we sought to modulate miR-501-3p levels using previously established methods. 25 First, using human HEK293 cells, we enhanced human miR-501-3p levels by transfecting with a miR-mimic (pre-miR) or reduced them using anti-miR ( Figure 3A) . Scrambled oligos (scr-miR) were used as transfection controls, and expression levels were confirmed by quantitative real-time polymerase chain reaction. As shown in Figure 3B , overexpression of miR-501-3p successfully resulted in decreased ZO-1 expression but did not alter claudin-5 or occludin. Affinity studies using luciferase constructs of the ZO-1 3′UTR confirmed binding of miR-501-3p in HEK293 cells, and miR-501-3p successfully regulated human ZO-1 in vitro ( Figure 3C ). This was further confirmed using an immortalized human brain endothelial cell line, hCMEC/ D3 ( Figure 3D ).
To determine whether miR-501-3p regulates ZO-1 in cerebral endothelial cells, we similarly modulated miR-501-3p in murine bEnd3 cells ( Figure 3E ). Interestingly, overexpression of miR-501-3p resulted in decreased ZO-1 and claudin-5 in bEnd3 cells ( Figure 3F ). Anti-miR-501-3p did not alter TJ gene expression compared with scrambled control, likely because of the fact that baseline miR-501-3p levels in these cells are low. Of note, pre-miR-501-3p decreased transendothelial electrical resistance ( Figure 3G ) and local ZO-1 protein expression ( Figure 3H ). ZO-1 and claudin-5 levels were further reduced by pre-miR-501-3p after TNFα stimulation, whereas anti-miR-501-3p significantly increased expression levels of ZO-1 (but not claudin-5) after TNFα stimulation ( Figure 3I ). TNFα reduced transendothelial electrical resistance, an effect that was enhanced by overexpression of miR-501-3p and was reversed with anti-miR-501-3p in cerebral endothelial cells ( Figure 3J ). Claudin-5 was regulated by miR-501-3p overexpression in mouse bEnd3 but not in human HEK239 cells, raising concerns of offtarget impacts. However, using primary mouse cerebral endothelial cells, overexpression of miR-501-3p decreased ZO-1 but not claudin-5 ( Figure 3K ). Additionally, premiR-501-3p significantly lowered transendothelial electrical resistance compared with scr-miR ( Figure 3L ). These results support the idea that TNFα combined with miR-501-3p induces BBB disruption by downregulating ZO-1, lowering cell-cell resistance.
Effects of Inhibiting miR-501-3p on White Matter BBB Disruption in the Cerebral Hypoperfusion-Induced VCI Murine Model
To determine whether miR-501-3p plays an important role in BBB disruption of VCI progression in vivo, we designed and created an LNA-modified anti-miR-501-3p ( Figure 4A ). Because antisense directed against miR-501-3p might also suppress miR-500-3p ( Figure IVA in the online-only Data Supplement), we tested target specificity and confirmed that anti-501-3p suppresses miR-501-3p but not miR-500-3p in vitro ( Figure IVB in the online-only Data Supplement).
FAM (fluorescein amidite)-labeled anti-miR-501-3p was detected only in the hearts and brains of BCAS mice ( Figure 4B ) at 48 hours after injection. Although there was concern for potential liver toxicity that might be induced by LNA-modified oligonucleotide, Figure 4B shows that there Unpaired t test was used in G. Bar=20 μm in bottom of G; 100 μm in top of G. n.c. indicates negative control.
was no signal detected from FAM-labeled anti-miR-501-3p in the liver region. Further, there were no obvious changes in liver morphology at euthanasia. There were no immediate differences in cerebral blood flow ratio between the treatment groups ( Figure 4C ) within 10 minutes of operation, nor were there changes in TNFα levels in the white matter ( Figure 4D ) at 48 hours when comparing the BCAS mice with anti-miR-501-3p-treated BCAS mice (dosed at 1 and 10 mg/kg-body weight). However, anti-miR-501-3p treatment reversed the BCAS-induced decrease in ZO-1 in the white matter ( Figure 4D ) at this time point (48 hours), without affecting the decrease in occludin levels ( Figure 4D ). After adjusting ZO-1 expression for expression of the endothelial cell marker CD31, high-dose anti-miR-501-3p significantly reversed the reduction of ZO-1 expression induced by BCAS surgery ( Figure 4E ). For this reason, high-dose antagomiR (10 mg/ kg) was used in subsequent experiments. Of note, Evans blue extravasation was increased in BCAS mouse brains, including white matter regions, whereas anti-501-3p-treated mice showed no difference from control non-BCAS mice ( Figure 4F ). Indeed, inhibiting miR-501-3p improved BBB disruption, as demonstrated by Evans blue extravasation in white matter regions after BCAS surgery at 48 hours compared with untreated BCAS mice ( Figure 4G ).
Effect of Inhibiting MiR-501-3p on Cognitive Function in the Cerebral HypoperfusionInduced VCI Murine Model
To maximize the potential for human translation, we next investigated the effects of inhibition of miR-501-3p on murine memory deficits using the BCAS mouse model. FAM-labeled anti-miR-501-3p was detected in the brains of BCAS mice at 28 days after injection ( Figure 5A ). As shown in Figure 5B , cerebral blood flow of BCAS mice treated with either scr-miR (control) or anti-miR-501-3p was significantly reduced compared with that of sham (non-BCAS) mice, both immediately post-operation and at 28 days. There was not a significant difference in the cerebral blood flow between scrambled miRtreated and anti-miR-501-3p-treated BCAS mice ( Figure 5B ) at either time point. Surprisingly, percent survival of BCAS mice was significantly improved by treatment with LNA-antimiR-501-3p ( Figure 5C ). Of particular note, anti-miR-501-3p significantly ameliorated the spatial working memory deficits of BCAS mice compared with scr-miR-treated BCAS mice in the Y-maze test ( Figure 5D ). Consistent with these findings, anti-501-3p also prevented white matter lesions ( Figure 5E ).
As reported previously, 13 BCAS surgery caused reference memory deficits. Here, sham (non-BCAS) mice demonstrated novel object preference in the NOR test, whereas BCAS mice lost this preference, and this change was not affected by scr-miR or anti-miR-501-3p ( Figure 6A-6C) . In support of these findings, scr-miR and anti-501-3p had no significant effect on BCAS-induced hippocampal injuries ( Figure 6D ). As mentioned above, we found no change in miR-501-3p hippocampal expression levels after BCAS ( Figure IIC in the online-only Data Supplement), which likely explains why anti-miR-501-3p had no impact on performance in this test. Indeed, hippocampal cerebral endothelial ZO-1 expression was not altered by the inhibition of miR-501-3p at the cellular level ( Figure IID in the online-only Data Supplement). Notably, BBB disruption was not apparent in the hippocampal area of both BCAS mice and anti-501-3p-treated BCAS mice ( Figure IIE in the online-only Data Supplement). It appears, therefore, that BCAS-induced hippocampal damage and the resultant reference memory deficits are not caused by BBB disruption.
Because cognition is strongly affected by motivational and emotional features, we monitored the anxiety response after BCAS surgery with and without anti-501-3p treatment. In the open-field test, there were no significant differences in the number of entries into the center area ( Figure 6E and 6F), although the stay time in the center area of both scrmiR-treated and anti-501-3p-treated BCAS mice decreased significantly from sham ( Figure 6G ). As shown in Figure 6H , the total travel distance increased in both scr-miR-treated and anti-501-3p-treated BCAS mice. Similarly, in the light and dark test, no changes in dark side area stay time were noted among the 3 groups ( Figure 6I ). Taken together, these results suggest that the BCAS procedure minimally affects the anxiety response, and no additional effect was seen with anti-501-3p.
Finally, using the wire hang test, we monitored the bar fall latency and found no differences between any of the treatment groups ( Figure 6J ), indicating that BCAS surgery and inhibition of miR-501-3p did not affect the motor system.
Discussion
In this study, we investigated the role of miRs in the progression of dementia induced by cerebral hypoperfusion. We showed that chronic cerebral hypoperfusion induces white matter lesions and cognitive impairment through BBB breakdown, at least in part using a pathway involving TNFα, miR-501-3p, and ZO-1. Using LNA-modified anti-miR-501-3p in the BCAS model, we ameliorated BBB disruption, partially corrected cerebral endothelial ZO-1 expression, and prevented working memory deficits. These studies suggest miR-501-3p as a potential therapeutic target for VCI.
Cerebrovascular damage is one of the main pathological processes leading to BBB disruption. BBB disruption plays an important role in cellular damage occurring in several neurological diseases, 38 including brain trauma, multiple sclerosis, and brain infections. 39 The importance of BBB disruption in the VCI process, especially in the white matter, has been extensively reported. 40 Abnormal permeability in the white matter in patients with VCI has been shown by dynamic contrast-enhanced magnetic resonance imaging, which is often used to evaluate the BBB. 41 Thus, the BBB is an extremely important factor to consider when treating neurological diseases, including VCI. Approaches using modification of BBB permeability have long been studied 28, 42 ; however, none have yet been translated to clinical practice. Of note, recent investigations have reported that miRs may regulate BBB function in several neurological conditions. For example, an important role for cerebral endothelial miR-155 at the BBB has been reported in patients with multiple sclerosis and in animal models. 43 Although miR expression profiles in cerebrospinal fluid and blood of patients with dementia, including VCI, have been investigated, no major candidates have been identified as biomarkers of BBB disruption. 44 Further, to our knowledge, there is currently no effective BBB-related treatment strategy or diagnostic method for dementia, including VCI. Thus, development of new therapeutic tools with a view to affecting BBB permeability warrants investigation.
Although direct inhibition of TNFα with antibody-and siRNA-based drugs might help limit dementia development, inhibition of miR-501-3p allows for broader targeting, influencing multiple gene targets and pathobiological processes. Indeed, DIANA-microT v5.0 identified 427 targets for mmu-miR-501-3p. Looking at pathway enrichment (DAVID Bioinformatics Resources 45 ), these targets were dominated in GOBio analysis by DNA-templated transcriptional regulators (102 genes; Figure VA in the online-only Data Supplement). The next most significantly enriched pathways included 21 nervous system genes and 12 neuron differentiation genes. Also significant were cell-cell adhesion molecules (17 genes). More interestingly, KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis suggested that miR-501-3p potentially regulates synaptic signaling of several varieties, as well as gap, adherens, and TJ genes (Figure VB in the online-only Data Supplement). Taken together, these findings suggest that miR-501-3p is a nerve tissue/central nervous system-related miR, which strongly affects transcriptional regulation and junctional proteins.
To date, only 2 publications have reported on the neurological role of miR-501-3p. One examined the contribution of miR-501-3p to synaptic plasticity. 46 The second, published recently (2017), reported that miR-501-3p is upregulated in autopsied brains (temporal cortex) of Alzheimer disease patients, although it was downregulated in serum. 47 These limited findings support our conclusion that miR-501-3p could become a therapeutic target and a biomarker for chronic cerebral hypoperfusion-induced dementia progression, known as VCI.
As a significant caveat, in the present study, we found that the TNFα-miR-501-3p-ZO-1 axis did not have any apparent effect on hippocampal damage. In studies using bilateral common carotid artery occlusion surgery, an alternative VCI murine model, hippocampal neuronal death also occurs and hippocampal TNFα levels increase. However, TNFα-deficient mice subjected to bilateral common carotid artery occlusion surgery continue to show hippocampal neuronal death, suggesting that TNFα is not a major contributor to this process. 48 In our hands, anti-miR-501-3p treatment failed unfortunately to ameliorate reference memory deficits in BCAS mice. This is likely because miR-501-3p was not upregulated in hippocampus post-BCAS surgery and suggests that hippocampal neuronal damage in VCI might not derive from BBB disruption. Notably, BBB disruption was not apparent in hippocampus of either BCAS mice or anti-miR-501-3p-treated BCAS mice. In fact, no Evans blue extravasation in rat hippocampi was previously noted in BCAS in comparison to sham. 49 The hippocampus is enriched in neuronal cells, whereas the white matter is enriched with myelin. Neuronal cells are particularly vulnerable to ischemia, suggesting that hippocampal damage may occur directly because of cerebral hypoperfusion. In previous work, we showed that ASK1 (apoptosis signal-regulating kinase 1)-deficient mice subjected to BCAS surgery did show improvements in reference memory when compared with controls. 13 Most likely, this related to the global nature of ASK1 deficiency, permitting amelioration in the hippocampus, a region largely unaffected in anti-501-3p-treated mice. This suggests that an alternative or additive therapeutic strategy to address hippocampal damage would be ideal.
Although we think BCAS is a promising model of VCI, a potential drawback is the acute drop in cerebral blood flow after common carotid artery manipulation followed by spontaneous blood flow recovery. Notably, we initiated anti-miR-501-3p treatments initiated 1 hour after placement of the BCAS coil, reasoning that miR-501-3p had started increasing 24 hours after surgery, with BBB disruption only identified later, and that no sustained upregulation of miR-501-3p levels at 28 days post-BCAS surgery was seen (data not shown). These data indicate miR-501-3p-ZO-1 most likely is involved in early-phase BBB disruption and would indicate why single administration of anti-501-3p was sufficient to rescue behavior and pathological findings several weeks after surgery. In a recent article, Hattori et al 20 reported on a new mouse model of VCI, which demonstrated gradual and continuous blood flow reduction as a result of carotid stenosis using an ameroid constrictor. Further investigation of this new murine model might assist in developing future therapeutic strategies in dementia.
Although we showed that miR-501-3p regulates ZO-1 and that delivery of antisense miR-501-3p can affect the behavioral deficits induced by cerebral hypoperfusion, definitive demonstration that the TJ changes are the cause of the behavioral changes are lacking. One approach to directly assess the role of ZO-1 would be to directly manipulate its expression level, and a study examining the impact on behavior of changing the expression of one tight-junction protein (claudin-5) was reported recently. 50 Those results, when added to those of our study, demonstrate the importance of TJ modulation as a therapeutic option for behavior disorders associated with BBB dysfunction. Further, because miR-501-3p regulated AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) signaling in the study of brain synaptic plasticity mentioned above, 46 modulation of miR-501-3p might also alter behavior through that mechanism. Further investigations are required.
There are several limitations to our study. Although previous studies had not reported any significant differences in locomotor activity between sham and BCAS mice, our study revealed increases in locomotor activity of BCAS mice treated with both scr-miR and anti-miR-501-3p. It is possible that the administration of oligonucleotide alone might lead to excitability; however, abnormal findings such as jumping, running, and vocalization were not observed during behavior tests. Second, our in vitro studies used a monoculture model. It is well known that the presence or astrocytes or pericytes can affect BBB features. Interactions of miR-501-3p with these other cell types as regards BBB function are worthy of future investigation.
Third, we did not measure cerebral blood flow at the 30-or 60-minute time points post-BCAS surgery, which might have been informative in determining whether the treatment affected the rate at which the vessels responded. Notably, TNFα can affect TJ permeability using other mechanisms beyond miR-501-3p. In fact, our previously published report showed that TNFα affects TJs via ASK1. 13 These effects might contribute at different time points than those we explored.
As a final point, NOR training and testing were performed 12 hours apart, resulting in testing during separate light/dark cycles, which might have affected data interpretation. Also, the sample size for NOR testing was somewhat smaller than the others because it was performed in the second cohort only.
In conclusion, we here provide the first evidence that the TNFα-miR-501-3p-ZO-1 axis plays an important role in the pathogenesis of cerebral hypoperfusion-induced working memory deficits and white matter lesions, as a result of BBB breakdown via TJ disruption ( Figure 6K ). We propose that inhibiting miR-501-3p could be a potential novel treatment for cognitive impairment induced by chronic cerebral hypoperfusion.
